Literature DB >> 25533673

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Lauren M Thorpe1, Haluk Yuzugullu2, Jean J Zhao2.   

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are crucial coordinators of intracellular signalling in response to extracellular stimuli. Hyperactivation of PI3K signalling cascades is one of the most common events in human cancers. In this Review, we discuss recent advances in our knowledge of the roles of specific PI3K isoforms in normal and oncogenic signalling, the different ways in which PI3K can be upregulated, and the current state and future potential of targeting this pathway in the clinic.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25533673      PMCID： PMC4384662          DOI： 10.1038/nrc3860

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  200 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

3.  Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

Authors:  Kyle C Kurek; Valerie L Luks; Ugur M Ayturk; Ahmad I Alomari; Steven J Fishman; Samantha A Spencer; John B Mulliken; Margot E Bowen; Guilherme L Yamamoto; Harry P W Kozakewich; Matthew L Warman
Journal:  Am J Hum Genet       Date:  2012-05-31       Impact factor: 11.025

4.  P110delta, a novel phosphoinositide 3-kinase in leukocytes.

Authors:  B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

5.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Authors:  Marie Will; Alice Can Ran Qin; Weiyi Toy; Zhan Yao; Vanessa Rodrik-Outmezguine; Claudia Schneider; Xiaodong Huang; Prashant Monian; Xuejun Jiang; Elisa de Stanchina; José Baselga; Ningshu Liu; Sarat Chandarlapaty; Neal Rosen
Journal:  Cancer Discov       Date:  2014-01-16       Impact factor: 39.397

6.  Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.

Authors:  Karin Reif; Klaus Okkenhaug; Takehiko Sasaki; Joseph M Penninger; Bart Vanhaesebroeck; Jason G Cyster
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

7.  Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.

Authors:  Evangelia A Papakonstanti; Olivier Zwaenepoel; Antonio Bilancio; Emily Burns; Gemma E Nock; Benjamin Houseman; Kevan Shokat; Anne J Ridley; Bart Vanhaesebroeck
Journal:  J Cell Sci       Date:  2008-11-25       Impact factor: 5.285

8.  The role of phosphoinositide 3-kinase C2alpha in insulin signaling.

Authors:  Marco Falasca; William E Hughes; Veronica Dominguez; Gianluca Sala; Florentia Fostira; Michelle Q Fang; Rosanna Cazzolli; Peter R Shepherd; David E James; Tania Maffucci
Journal:  J Biol Chem       Date:  2007-07-20       Impact factor: 5.157

9.  Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.

Authors:  Inma M Berenjeno; Julie Guillermet-Guibert; Wayne Pearce; Alexander Gray; Stewart Fleming; Bart Vanhaesebroeck
Journal:  Biochem J       Date:  2012-02-15       Impact factor: 3.857

10.  Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

Authors:  John E Burke; Olga Perisic; Glenn R Masson; Oscar Vadas; Roger L Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205
View more
  443 in total

1.  New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Zeng-Feng Wang; Markku Miettinen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2019-01

2.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

3.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

Authors:  Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

Review 4.  Mitochondrial dynamics as regulators of cancer biology.

Authors:  Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

5.  CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

Authors:  Jing Zhang; Xueliang Gao; Fabienne Schmit; Guillaume Adelmant; Michael J Eck; Jarrod A Marto; Jean J Zhao; Thomas M Roberts
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

6.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

7.  A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

Authors:  Jae-Hyeog Choi; Ki Hyang Kim; Kug-Hwan Roh; Hana Jung; Anbok Lee; Ji-Young Lee; Joo Yeon Song; Seung Jae Park; Ilhwan Kim; Won-Sik Lee; Su-Kil Seo; Il-Whan Choi; Yang-Xin Fu; Sung Su Yea; SaeGwang Park
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

Review 8.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

9.  Molecular profiling of clear cell adenocarcinoma of the urinary tract.

Authors:  Chieh-Yu Lin; Atif Saleem; Henning Stehr; James L Zehnder; Benjamin A Pinsky; Christian A Kunder
Journal:  Virchows Arch       Date:  2019-08-02       Impact factor: 4.064

10.  Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.

Authors:  Catherine A Evans; Tao Liu; André Lescarbeau; Somarajan J Nair; Louis Grenier; Johan A Pradeilles; Quentin Glenadel; Thomas Tibbitts; Ann M Rowley; Jonathan P DiNitto; Erin E Brophy; Erin L O'Hearn; Janid A Ali; David G Winkler; Stanley I Goldstein; Patrick O'Hearn; Christian M Martin; Jennifer G Hoyt; John R Soglia; Culver Cheung; Melissa M Pink; Jennifer L Proctor; Vito J Palombella; Martin R Tremblay; Alfredo C Castro
Journal:  ACS Med Chem Lett       Date:  2016-07-22       Impact factor: 4.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.